Prognosis of ovarian cancer subsequent to venous thromboembolism: A nationwide Danish cohort study

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Tetsche, Mette S ^a,b   Nørgaard, Mette ^a   Pedersen, Lars ^a   Lash, Timothy L ^c   Sørensen, Henrik T ^a,c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TIME SERIES ANALYSIS; VENOUS THROMBOEMBOLISM; VITAL SIGN;

AGED; COHORT STUDIES; DENMARK; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; THROMBOEMBOLISM; TIME FACTORS;

EID: 33748697684     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-189     Document Type: Article

References (26)

1. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL: The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998, 338:1169-1173.
2. Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW: Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992, 327:1128-1133.
3. Baron JA, Gridley G, Weiderpass E, Nyren O, Linet M: Venous thromboembolism and cancer. Lancet 1998, 351:1077-1080.
4. Bjorge T, Engeland A, Sundfor K, Trope CG: Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-94 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 1998, 77:777-781.
5. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C: Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000, 78:21-27.
6. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA: Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000, 343:1846-1850.
7. Illtyd James TG, Matheson NM: Thrombo-Phlebitis in cancer. Practitioner 1935, 134:683-684.
8. Cooper T, Barker NW: Recurrent venous thrombosis: An early complication of obscure visceral carcinoma. Minn Med 1944, 27:31-36.
9. White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, Wun T: Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med 2005, 165:1782-1787.
10. Storm HH, Michelsen EV, Clemmensen IH, Pihl J: The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997, 44:535-539.
11. Staging classifications and clinical practice guidelines of gynaecologic cancers [http://www.figo.org/content/PDF/staging-booklet.pdf]
12. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH: The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999, 46:263-268.
13. Cancer Incidence in Denmark 1999 National Broad of Health, Health Statistics, Copenhagen; 2003.
14. Klassifikation of sygdomme, 10th revision Sundhedsstyrelsen, Copenhagen; 1986.
15. Klassifikation of sygdomme, 10th revision Sundhedsstyrelsen, Copenhagen; 1993.
16. Kirkwood BR, Sterne JA: Medical Statistics Blackwell Publishing, Oxford; 2003.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
18. Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A: Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Cancer 2004, 14:1086-1096.
19. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi M, Enokida H, Verma M, Dahiya R: WTI and WTI-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005, 104:1924-1930.
20. Pather S, Quinn MA: Clear-cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer 2005, 15:432-437.
21. Schulman S, Lindmarker P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 2000, 342:1953-1958.
22. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen M, Trope CG: Prognostic importance of degree of differentiation and cyst rupture in stage 1 invasive epithelial ovarian carcinoma. Lancet 2001, 357:176-182.
23. von Tempelhoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L: Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997, 77:456-461.
24. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005, 23:2130-2135.
25. von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ, Heilmann L: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol 2000, 16:815-824.
26. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948.